New

Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →

Help us improve your experience. Please confirm your investor type:

Compare ETFs Easily

The Ultimate ETF Comparison Tool - Try Now!

Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.

Start Comparing ETFs Now!

›ETF Providers›Tema›CANC

CANC

US87975E7013

Active ETF Equity Theme: Tomorrow's Treatments

CANC ETF · Tema Oncology ETF

The CANC Exchange Traded Fund (ETF) is provided by Tema. This fund is actively managed; it does not track an index. This share class generates a stream of income by distributing dividends.

Last update 4/2/2026, 1:30 PM UTC

LIVE

CLOSED

This fund is part ofTomorrow's Treatments1M perf.-1.29%

Last price

$37.11

1M perf.

-0.74%

1M flows

+€11M

AuM

€148M

E/R

0.99%

Rating

Not rated

ESG Consensus®

CANC

$37.11

Performance & flows

Segment for quartile rank

January 2, 2026 → April 2, 2026

Create a free account to view the flows graph

CANC

$37.07

+7.36%

Tomorrow's Treatments

+4.10%

Historic performance and flows

	1M	3M	1Y	3Y	5Y	MTD	QTD	YTD
Perf.	-0.74%	+7.36%	+55.28%	N/A	N/A	+1.34%	+1.34%	+7.01%
Flows

Key fund info

Segment for quartile rank

This ETF's jurisdiction country is not in your region (Europe and Middle East) ·

Main characteristics

Issuer

Tema

CUSIP

87975E701

ISIN

US87975E7013

AuM

€148M

E/R

0.99%

ESG Consensus®

More details

NAV

4/2/2026

$37.07

1D NAV change

+0.28%

Dividend policy

Distributing

No. of holdings

Inception date

8/15/2023

Jurisdiction

United States

Distribution

United States

Legal structure

Open-end Investment Company

Base currency

USD

Dividend distribution

Trailing 12-month distr. yield

Distribution frequency

Last distribution

Create a free account to view dividend distribution

Classification

Product type

Active ETF

Asset class

Equity

Factors

N/A

Investment strategy

Tema Oncology ETF (the “Fund”) seeks to provide long-term growth

Tax optimisation

PEA

France

UK Reporting Status

United Kingdom

Create a free Trackinsight Essentials account to unlock insights

Access exclusive metrics and features to support your investment decisions.

Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.

Enterprise Fund page features include:

Legal documents

Powerful buy-list integration

Fund data exports

Advanced risk metrics

Advanced replication analysis

Advanced exposure look-through

Upload your own internal metrics

Custom data feature

See all Trackinsight Enterprise features

Enterprise

Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.

Learn more about Trackinsight Enterprise

Similar ETFs in your region

WDNA

WisdomTree BioRevolution Fund

1M perf.

-2.88%

E/R

0.45%

WDNA

WisdomTree BioRevolution UCITS ETF

1M perf.

-2.96%

E/R

0.45%

GNOG

Global X Genomics & Biotechnology UCITS ETF

1M perf.

-5.91%

E/R

0.5%

GNOM

Global X Genomics & Biotechnology ETF - USD

1M perf.

-5.92%

E/R

0.5%

DOCG

L&G Healthcare Technology & Innovation UCITS ETF

1M perf.

-6.35%

E/R

0.49%

Risk profile

Segment for quartile rank

Historical risk/return profile

	3M	1Y	3Y	5Y
Returns	+7.36%	+55.28%	N/A	N/A
Volatility
Perf./Volatility
Max drawdown

Create a free account to view risk/return table

Synthetic Risk and Reward Indicator (SRRI)

UCITS

N/A

PRIIPS

N/A

More exposure metrics are available, exclusively in Trackinsight Enterprise

Exposure

Countries

USA

87.74%

Switzerland

4.87%

United Kingdom

4.56%

Japan

1.24%

Unavailable

0.72%

Other

0.87%

Sectors

Health Care

81.69%

Unavailable

18.31%

Diversification

Total weight of top 15 holdings out of 55

Top 15 holdings

Data as of February 28, 2026

REVOLUTION MEDICINES INC

NOVARTIS

BRIDGEBIO PHARMA

ASTRAZENECA

LILLY

BRISTOL-MYERS SQUIBB

US7711951043

MERCK & CO INC

Create a free account to view top holdings

ARCELLX

COGENT BIOSCIENCES

NUVALENT

US3723032062

IMMUNOME

JOHNSON&JOHNSON

AMGEN-T

Create a free account to view top holdings

More risk metrics are available, exclusively in Trackinsight Enterprise

Sustainability

Integrates ESG criteria

SDG

More sustainability metrics are available, exclusively in Trackinsight Enterprise

Issuer

Tema

Tema ID Card

Number of funds

Total AuM

€1.52B

Expense ratio range

0.18% - 0.99%

Average expense ratio

0.774%

View all Tema funds

Top 5 funds by Tema

		AuM
DSPY	Tema S&P 500 Historical Weight ETF Strategy	€670M
VOLT	Tema Electrification ETF	€399M
RSHO	Tema American Reshoring ETF	€200M
CANC	Tema Oncology ETF	€148M
HRTS	Tema GLP-1, Obesity & Cardiometabolic ETF	€44M

Frequently asked questions about CANC

What does Tema Oncology ETF, CANC, invest in?

CANC is a Active ETF. This ETF provides exposure to Other Equities.

What is the Total Expense ratio (TER) of CANC?

CANC carries a total expense ratio (TER) of 0.99%, indicating the annual cost for holding the fund.

When was CANC launched?

CANC was introduced to the market on August 15, 2023. It trades on United States

Who is the ETF issuer of CANC?

Tema Oncology ETF, CANC, is provided by Tema. Learn more about Tema here.

What is the current assets under management (AUM) of CANC?

CANC oversees €148M in assets as of April 2, 2026.

How has CANC performed lately?

Based on data from April 2, 2026, CANC returned -0.74% over the past month, 7.36% over the last three months and 7.01% year-to-date.

What are the latest inflows or outflows for CANC?

As of April 2, 2026, CANC recorded net flows of +€11M over the last month and +€39M year-to-date.

Does CANC distribute dividends?

CANC follows a distributing dividend policy, meaning it pays out income to investors. As of April 2, 2026, its 12-month trailing yield was 0.05%.

What are the main country or region exposures of CANC?

As of February 28, 2026, CANC has significant geographic allocations in USA, Switzerland and United Kingdom.

In which sector or theme does CANC invest in?

As of February 28, 2026, CANC focuses largely on Health Care.

How many securities does CANC hold and how diversified is it?

As of February 28, 2026, CANC holds 55 positions in its portfolio, with 57.80% of assets concentrated in its top 15 holdings.

What are the main positions in CANC?

As of February 28, 2026, CANC top three holdings include REVOLUTION MEDICINES INC, NOVARTIS and BRIDGEBIO PHARMA.

What is the base currency of CANC?

The base currency of CANC is USD.

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

The Ultimate ETF Comparison Tool - Try Now!

CANC ETF · Tema Oncology ETF

Performance & flows

Historic performance and flows

Monthly performance and flows

Trading and listing info

Key fund info

Enterprise

Similar ETFs in your region

Risk profile

Historical risk/return profile

Exposure

Sustainability

Issuer

Frequently asked questions about CANC

What does Tema Oncology ETF, CANC, invest in?

CANC is a Active ETF. This ETF provides exposure to Other Equities.

What is the Total Expense ratio (TER) of CANC?

CANC carries a total expense ratio (TER) of 0.99%, indicating the annual cost for holding the fund.

When was CANC launched?

CANC was introduced to the market on August 15, 2023. It trades on United States

Who is the ETF issuer of CANC?

Tema Oncology ETF, CANC, is provided by Tema. Learn more about Tema here.

What is the current assets under management (AUM) of CANC?

CANC oversees €148M in assets as of April 2, 2026.

How has CANC performed lately?

Based on data from April 2, 2026, CANC returned -0.74% over the past month, 7.36% over the last three months and 7.01% year-to-date.

What are the latest inflows or outflows for CANC?

As of April 2, 2026, CANC recorded net flows of +€11M over the last month and +€39M year-to-date.

Does CANC distribute dividends?

CANC follows a distributing dividend policy, meaning it pays out income to investors. As of April 2, 2026, its 12-month trailing yield was 0.05%.

What are the main country or region exposures of CANC?

As of February 28, 2026, CANC has significant geographic allocations in USA, Switzerland and United Kingdom.

In which sector or theme does CANC invest in?

As of February 28, 2026, CANC focuses largely on Health Care.

How many securities does CANC hold and how diversified is it?

As of February 28, 2026, CANC holds 55 positions in its portfolio, with 57.80% of assets concentrated in its top 15 holdings.

What are the main positions in CANC?

As of February 28, 2026, CANC top three holdings include REVOLUTION MEDICINES INC, NOVARTIS and BRIDGEBIO PHARMA.

What is the base currency of CANC?

The base currency of CANC is USD.

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US